{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:13Z","timestamp":1793083993265,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cap48 (Radio-T\u00e9l\u00e9vision belge de la Communaut\u00e9 fran\u00e7aise"},{"name":"King Baudouin Foundation (Fund for scientific research in rheumatology (FWRO-FRSR)).","award":["2022-J1820590-227862"],"award-info":[{"award-number":["2022-J1820590-227862"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care in early RA trial. This study aimed to determine the association of this antibody panel with first-line therapy response in an independent cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Anti-UH-RA.305\/318\/329 antibody reactivity was determined using ELISA in 165 baseline samples of the CAP48 cohort, an observational cohort of patients with early and na\u00efve RA treated mainly with methotrexate monotherapy. Multivariable analyses assessed associations between baseline antibody reactivity and failure to reach remission or low disease activity (LDA) at 3, 6, 9 and 24 months according to the Disease Activity Score 28-joint C-reactive protein (DAS28CRP) and clinical\/simplified disease activity index (SDAI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the total RA cohort, baseline anti-UH-RA.305\/318\/329 antibody reactivity was significantly higher in patients not achieving LDA versus those achieving LDA at 9 months (31.6% vs 11.3% for DAS28CRP\/SDAI; OR 3.64, 95%\u2009CI 1.34 to 9.91, p=0.045). In patients with seronegative RA, a significant association between antibody reactivity and not achieving LDA based on DAS28CRP (42.1% vs 12.5%; OR 5.09, 95%\u2009CI 1.2 to 27.0, p=0.05) was already observed at 6 months. After 24 months, baseline antibody positivity remained significantly associated with not achieving LDA based on SDAI (OR 29.9, 95%\u2009CI 2.5 to 109.2, p=0.01) in patients with seronegative status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In the CAP48 cohort, the anti-UH-RA antibody panel was associated with a lack of response to first-line therapy for certain clinical measures, observed at 9 months in the total RA cohort and at 6 and 24 months in patients with seronegative status. The antibody panel should be further validated for its use in early personalised RA treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006407","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:35:18Z","timestamp":1773412518000},"page":"e006407","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort"],"prefix":"10.1136","volume":"12","author":[{"given":"Sukayna","family":"Fadlallah","sequence":"first","affiliation":[{"name":"Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fraussen","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Ruytinx","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sokolova","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc - Universit\u00e9 catholique de Louvain (UCLouvain), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), Rheumatology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KULeuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint-Luc - Universit\u00e9 catholique de Louvain (UCLouvain), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), Rheumatology, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-8724","authenticated-orcid":false,"given":"Veerle","family":"Somers","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026031307351309000_12.1.e006407.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8"},{"key":"2026031307351309000_12.1.e006407.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026031307351309000_12.1.e006407.3","first-page":"1631","article-title":"Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study","volume":"29","author":"Aletaha","year":"2002","journal-title":"J Rheumatol"},{"key":"2026031307351309000_12.1.e006407.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez213"},{"key":"2026031307351309000_12.1.e006407.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205489"},{"key":"2026031307351309000_12.1.e006407.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208324"},{"key":"2026031307351309000_12.1.e006407.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2022.105491"},{"key":"2026031307351309000_12.1.e006407.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.27692"},{"key":"2026031307351309000_12.1.e006407.9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.41499","article-title":"Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort","volume":"73","author":"Holdren","year":"2021","journal-title":"Arthritis & Rheumatology"},{"key":"2026031307351309000_12.1.e006407.10","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care & Research"},{"key":"2026031307351309000_12.1.e006407.11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424792112"},{"key":"2026031307351309000_12.1.e006407.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03384-9","article-title":"Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort","volume":"26","author":"Natalucci","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026031307351309000_12.1.e006407.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02851-5","article-title":"Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data","volume":"24","author":"Duong","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026031307351309000_12.1.e006407.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139212"},{"key":"2026031307351309000_12.1.e006407.15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.reuma.2009.02.002","article-title":"Cytokine biomarkers and the promise of personalized therapy in rheumatoid arthritis","volume":"5","author":"Davis","year":"2009","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"2026031307351309000_12.1.e006407.16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/ijr.12.57","article-title":"Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis","volume":"7","author":"Verstappen","year":"2012","journal-title":"Int J Clin Rheumtol"},{"key":"2026031307351309000_12.1.e006407.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.088237"},{"key":"2026031307351309000_12.1.e006407.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201117"},{"key":"2026031307351309000_12.1.e006407.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF\u03b1 agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLoS ONE"},{"key":"2026031307351309000_12.1.e006407.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22640"},{"key":"2026031307351309000_12.1.e006407.21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004743","article-title":"Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis","volume":"10","author":"Vandormael","year":"2024","journal-title":"RMD Open"},{"key":"2026031307351309000_12.1.e006407.22","unstructured":"Dierckx S , Sapart E , Sokolova T , et al . Het Belgian CAP48 RA Cohort: Het Belang Van Vroege Remis. Ortho-Rheumato 2020;18."},{"key":"2026031307351309000_12.1.e006407.23","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/art.41427","article-title":"Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent Cohorts","volume":"72","author":"Quaden","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026031307351309000_12.1.e006407.24","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780090710"},{"key":"2026031307351309000_12.1.e006407.25","doi-asserted-by":"crossref","unstructured":"Verschueren P , De Cock D , Corluy L , et al . n.d. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Arthritis Res Ther 17:97. doi:10.1186\/s13075-015-0611-8","DOI":"10.1186\/s13075-015-0611-8"},{"key":"2026031307351309000_12.1.e006407.26","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600780219"},{"key":"2026031307351309000_12.1.e006407.27","doi-asserted-by":"crossref","first-page":"1759720X221096363","DOI":"10.1177\/1759720X221096363","article-title":"Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry","volume":"14","author":"Koh","year":"2022","journal-title":"Therapeutic Advances in Musculoskeletal"},{"key":"2026031307351309000_12.1.e006407.28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06584-y","article-title":"Increased remission with fewer corticosteroids and more biologics in rheumatoid arthritis at 7-year follow-up in real-life conditions","volume":"12","author":"Larid","year":"2022","journal-title":"Sci Rep"},{"key":"2026031307351309000_12.1.e006407.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204020"},{"key":"2026031307351309000_12.1.e006407.30","article-title":"Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region","volume":"15","author":"Sun","year":"2021","journal-title":"Lancet Reg Health West Pac"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:35:22Z","timestamp":1773412522000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006407"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006407","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}